IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Study IMVT-1401-3201 is a Phase 3, multi-center, randomized, quadruple‑masked (Sponsor, Investigator, assessor, and participant), placebo‑controlled study was designed to assess the efficacy and safety of batoclimab in adult participants with active, moderate to severe TED. The study duration for an individual participant may be up to 32 weeks.
MoreAdult
The study population will consist of participants 18 years or older who have active, moderate to severe TED.
Treatment
University of Colorado Hospital
Prem Subramanian, MD, PhD
Protocol Number: 22-1591
More information available at ClinicalTrials.gov: NCT05517421
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers